Meeting Report
Improving Outcomes for Women With Metastatic HER2-Positive and HER2-Low Breast Cancer
Presented by Stephanie L. Graff,(1,2) MD, FACP, FASCO, Christine McGinn,(1) MSN, APRN, ACNP-BC, and Jeanine R. Showalter,(3) MSN, APRN, FNP-BC, AOCNP®
Presenters’ disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2024;15(3):187–190 |
https://doi.org/10.6004/jadpro.2024.15.3.6 |
© 2024 BroadcastMed LLC
ABSTRACT
At JADPRO Live 2023, presenters discussed recent updates to clinical practice in metastatic HER2-positive metastatic breast cancer. During the session, they reviewed review recent FDA approvals, the clinical relevance of HER2-low status, and evidence-based practices for managing adverse events associated with novel HER2 agents.
For access to the full length article, please
sign in.
